Neuronetics, Inc. (STIM) News

Neuronetics, Inc. (STIM): $6.43

0.04 (+0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter STIM News Items

STIM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

STIM News Highlights

  • STIM's 30 day story count now stands at 25.
  • Over the past 10 days, the trend for STIM's stories per day has been choppy and unclear. It has oscillated between 1 and 11.
  • BWAY, GBNH and ACT are the most mentioned tickers in articles about STIM.

Latest STIM News From Around the Web

Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.

Neuronetics Inks Six-Year Exclusive Partnership With Greenbrook TMS

Neuronetics Inc (NASDAQ: STIM ) and Greenbrook TMS Inc (NASDAQ: GBNH ) announced an expanded commercial partnership through year-end 2028 . Under the partnership agreement, Neuronetics will be the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to Greenbrook. Over time, Neuronetics'' NeuroStar devices will replace competitive … Full story available on Benzinga.com

Benzinga | January 19, 2023

STIM stock gains on six-year deal with Greenbrook for depression therapy (NASDAQ:STIM)

Neuronetics, Inc. (STIM) and Canada-based mental care provider Greenbrook TMS (GBNH) announced a six-year deal on Thursday for TMS devices. Read the full story here.

Seeking Alpha | January 19, 2023

Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership

MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders (“Neuronetics”), and Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH), a leading provider of transcranial magnetic stimulation (“TMS”) therapy (“Greenbrook”), today announced an expanded commercial partnership thro

Yahoo | January 19, 2023

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Neuronetics’ Compensation Committee and made as a material induce

Yahoo | January 18, 2023

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar Advanced Therapy for Mental Health

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today

Wallstreet:Online | January 17, 2023

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxietyMALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced a new peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world evid

Yahoo | January 17, 2023

Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay

Neuronetics Inc (NASDAQ: STIM ) settled the litigation filed in the District of Delaware against BrainsWay Ltd (NASDAQ: BWAY ) and BrainsWay USA Inc. for unfair competition. Under the terms of the settlement, BrainsWay agreed to stop using the efficacy data for the treatment of anxious depression with NeuroStar Advanced … Full story available on Benzinga.com

Benzinga | January 10, 2023

Neuronetics Settles Litigation Against BrainsWay

MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has settled the litigation filed in the District of Delaware against BrainsWay Ltd. and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law.

GlobeNewswire | January 10, 2023

BrainsWay resolves unfair competition litigation with Neuronetics

BrainsWay (BWAY) has settled an unfair competition litigation with Neuronetics (STIM). Read more on the settlement here.

Seeking Alpha | January 10, 2023

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain preliminary unaudited fourth quarter and full year 2022 revenue results.

GlobeNewswire | January 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5572 seconds.